Akifumi Fujii

A phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of etelcalcetide (ONO-5163/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese haemodialysis patients

Masafumi Fukagawa, Keitaro Yokoyama, Takashi Shigematsu et al. · Nephrology Dialysis Transplantation · 2016 · 59 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of the Rivastigmine Patch in Japanese Patients with Alzheimer’s Disease

Yu Nakamura, Yukimichi Imai, Masahiro Shigeta et al. · Dementia and Geriatric Cognitive Disorders Extra · 2011 · 50 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12

Long-term effects of etelcalcetide as intravenous calcimimetic therapy in hemodialysis patients with secondary hyperparathyroidism

Takashi Shigematsu, Masafumi Fukagawa, Keitaro Yokoyama et al. · Clinical and Experimental Nephrology · 2017 · 29 citations

Medicine, Endocrinology, Nephrology +15

Ocular Hypotensive Effect of ONO-9054, an EP3/FP Receptor Agonist: Results of a Randomized, Placebo-controlled, Dose Escalation Study

Alon Harris, Caroline L. Ward, Cheryl L. Rowe-Rendleman et al. · Journal of Glaucoma · 2016 · 23 citations · Full text

Medicine, Ophthalmology, Pharmacology +15

Effects of the Intravenous Calcimimetic Etelcalcetide on Bone Turnover and Serum Fibroblast Growth Factor 23: Post Hoc Analysis of an Open-label Study

Takashi Shigematsu, Masafumi Fukagawa, Keitaro Yokoyama et al. · Clinical Therapeutics · 2018 · 19 citations · Full text

Medicine, Endocrinology, Nephrology +17